Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)- 5-trifluoromethyl-phenyl]-3-(4-pyridin-3yl-pyrimidin-2-ylamino)-benzamide

Details for Australian Patent Application No. 2012201453 (hide)

Owner Novartis AG

Inventors Brozio, Jorg; Sutton, Paul Allen; Manley, Paul W.; Shieh, Wen-Chung; Wu, Raeann; Monnier, Stephanie; Karpinski, Piotr H.

Agent Davies Collison Cave

Pub. Number AU-A-2012201453

Parent 2011202047

Filing date 9 March 2012

Wipo publication date 5 April 2012

International Classifications

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

29 March 2012 Complete Application Filed

5 April 2012 Application Open to Public Inspection

  Published as AU-A-2012201453

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012201454-Method for eliminating spectral constraints of acquisition system and earth filtering effects

2012201452-Method and apparatus for irrigation system design registration and on-site sprinkler package configuration verification